文献速递造血干细胞移植与细胞治疗

白血病抑制因子预防移植物抗宿主病同时保留移植物抗白血病活性

Leukemia inhibitory factor protects against graft-versus-host disease while preserving graft-versus-leukemia activity.
PubMed 文献 · Blood · 2022-01-01

该研究在小鼠模型中报道了白血病抑制因子(LIF)对移植物抗宿主病(GVHD)的保护作用:给予重组LIF蛋白可减轻GVHD所致组织损伤和致死率,同时不损害移植物抗白血病活性;机制上rLIF通过激活STAT1下调受者树突状细胞IL-12-p40表达,降低肠道上皮细胞MHC II水平及供者T细胞活化与浸润。

要点

  • 重组LIF蛋白可保护小鼠免受GVHD所致组织损伤和致死,且不损害移植物抗白血病活性。
  • rLIF减少供者免疫细胞浸润与活化,并保护肠道干细胞以改善GVHD。
  • 机制为rLIF经STAT1下调受者树突状细胞IL-12-p40,降低肠道上皮MHC II及供者T细胞活化。

核心结论

  • 本研究揭示LIF对GVHD所致组织病理具有此前未识别的保护作用,并提供一种在不损害抗白血病疗效的前提下限制组织病理的潜在有效治疗策略。

研究设计与样本

  • 在小鼠模型中给予重组LIF蛋白(rLIF)以观察其对GVHD及移植物抗白血病活性的影响。

主要发现

  • 给予rLIF保护小鼠免受GVHD诱导的组织损伤和致死,且不损害移植物抗白血病活性。
  • rLIF减少供者免疫细胞的浸润和活化,并保护肠道干细胞以改善GVHD。
  • rLIF通过激活STAT1信号下调受照后受者树突状细胞中IL-12-p40表达,导致肠道上皮细胞主要组织相容性复合体II水平降低及供者T细胞活化和浸润减少。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GVHD) remains a major complication after allogeneic hematopoietic stem cell transplantation, a widely used therapy for hematologic malignancies and blood disorders. Here, we report an unexpected role of cytokine leukemia inhibitory factor (LIF) in protecting against GVHD development. Administrating recombinant LIF protein (rLIF) protects mice from GVHD-induced tissue damage and lethality without compromising the graft-versus-leukemia activity, which is crucial to prevent tumor relapse. We found that rLIF decreases the infiltration and activation of donor immune cells and protects intestinal stem cells to ameliorate GVHD. Mechanistically, rLIF downregulates IL-12-p40 expression in recipient dendritic cells after irradiation through activating STAT1 signaling, which results in decreased major histocompatibility complex II levels on intestinal epithelial cells and decreased donor T-cell activation and infiltration. This study reveals a previously unidentified protective role of LIF for GVHD-induced tissue pathology and provides a potential effective therapeutic strategy to limit tissue pathology without compromising antileukemic efficacy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Wang J, Chang CY, Yang X, et al. Leukemia inhibitory factor protects against graft-versus-host disease while preserving graft-versus-leukemia activity. Blood. 2022. PMID: 35981499. doi:10.1182/blood.2022015677

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。